News
CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...
The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...
4d
GlobalData on MSNBeOne Medicines’ BTK degrader gains EMA PRIME designationThe designation was based on the therapy’s novel mechanism and data showing its anti-tumour activity in B-cell malignancies.
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to ...
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in ...
Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...
LONDON -- The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission.
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
Moderna (Nasdaq: MRNA) has secured European clearance for its latest version of Spikevax (elasomeran) for individuals aged ...
A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...
Beone Medicines Receives Positive CHMP Opinion For TEVIMBRA® In Neoadjuvant/Adjuvant NSCLC Treatment
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Commi ...
"Tevimbra is already approved in the EU across multiple settings in [non-small cell lung cancer], the most common form of lung cancer, and this positive CHMP opinion expands its potential to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results